{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:35:49Z","timestamp":1793262949786,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.xphs.2026.104562","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:12:29Z","timestamp":1792771949000},"page":"104562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In silico and in vitro immunogenicity risk assessment of process- and product-related protein impurities reported in adenoviral-vectored COVID-19 vaccines"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5911-1459","authenticated-orcid":false,"given":"Anne S.","family":"De Groot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamako","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibha","family":"Jawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104562_bib0001","unstructured":"United States Food and Drug Administration. Code of Federal Regulations, Title 21, Part 610.13: Purity. Rockville (MD): US Food and Drug Administration; 2018."},{"key":"10.1016\/j.xphs.2026.104562_bib0002","unstructured":"United States Pharmacopeial Convention. Residual host cell protein measurement in biopharmaceuticals. USP 39\u2013NF 34 <1132>. Bethesda (MD): United States Pharmacopeial Convention; 2016."},{"key":"10.1016\/j.xphs.2026.104562_bib0003","series-title":"ICH Q6B: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use","year":"1999"},{"key":"10.1016\/j.xphs.2026.104562_bib0004","series-title":"Guideline 3AB1A: Production and Quality Control of Medicinal Products Derived by Recombinant DNA Technology","year":"1995"},{"issue":"2","key":"10.1016\/j.xphs.2026.104562_bib0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejh.13665","article-title":"COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome","volume":"107","author":"Franchini","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.xphs.2026.104562_bib0006","unstructured":"J. Gallager, AstraZeneca to withdraw Covid vaccine, BBC2024. https:\/\/www.bbc.com\/news\/health-68977026 Last Accessed Sept 6, 2026."},{"issue":"19","key":"10.1016\/j.xphs.2026.104562_bib0007","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.3390\/jcm12196126","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis (VITT): insights from clinical cases, in vitro studies and murine models","volume":"12","author":"Dabbiru","year":"2023","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.xphs.2026.104562_bib0008","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMoa2514824","article-title":"Adenoviral inciting antigen and somatic hypermutation in VITT","volume":"394","author":"Wang","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2026.104562_bib0009","series-title":"Omnitrope (somatropin): EPAR Scientific Discussion","year":"2006"},{"issue":"2","key":"10.1016\/j.xphs.2026.104562_bib0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jps.22276","article-title":"Impact of product-related factors on immunogenicity of biotherapeutics","volume":"100","author":"Singh","year":"2011","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2026.104562_bib0011","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/bcp.13938","article-title":"Adverse immunostimulation caused by impurities: the dark side of biopharmaceuticals","volume":"85","author":"Reijers","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2026.104562_bib0012","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/btpr.2640","article-title":"Experience with host cell protein impurities in biopharmaceuticals","volume":"34","author":"Vanderlaan","year":"2018","journal-title":"Biotechnol Prog"},{"issue":"3","key":"10.1016\/j.xphs.2026.104562_bib0013","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/bit.22304","article-title":"Host cell proteins in biologics development: identification, quantitation and risk assessment","volume":"103","author":"Wang","year":"2009","journal-title":"Biotechnol Bioeng"},{"issue":"7","key":"10.1016\/j.xphs.2026.104562_bib0014","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/bit.27808","article-title":"High-risk\u201d host cell proteins (HCPs): a multi-company collaborative view","volume":"118","author":"Jones","year":"2021","journal-title":"Biotechnol Bioeng"},{"issue":"9","key":"10.1016\/j.xphs.2026.104562_bib0015","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/bit.25628","article-title":"The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control","volume":"112","author":"Bracewell","year":"2015","journal-title":"Biotechnol Bioeng"},{"issue":"5","key":"10.1016\/j.xphs.2026.104562_bib0016","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11095-025-03843-1","article-title":"Immunogenicity of generic peptide impurities: current orthogonal approaches","volume":"42","author":"De Groot","year":"2025","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2026.104562_bib0017","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/bit.25286","article-title":"CHOPPI: a web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production","volume":"111","author":"Bailey-Kellogg","year":"2014","journal-title":"Biotechnol Bioeng"},{"issue":"12","key":"10.1016\/j.xphs.2026.104562_bib0018","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.4161\/hv.36134","article-title":"Immune camouflage: relevance to vaccines and human immunology","volume":"10","author":"De Groot","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.xphs.2026.104562_bib0019","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2333729","article-title":"In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies","volume":"16","author":"Mattei","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104562_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1730346","article-title":"Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products","volume":"16","author":"Mattei","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104562_bib0021","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78513","article-title":"Process- and product-related impurities in the ChAdOx1 nCoV-19 vaccine","volume":"11","author":"Krutzke","year":"2022","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.xphs.2026.104562_bib0022","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clim.2007.03.544","article-title":"Clinical validation of the \u201cin silico\u201d prediction of immunogenicity of a human recombinant therapeutic protein","volume":"124","author":"Koren","year":"2007","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.xphs.2026.104562_bib0023","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1002\/bit.28112","article-title":"Holistic analytical characterization and risk assessment of residual host cell protein impurities in an active pharmaceutical ingredient synthesized by biocatalysts","volume":"119","author":"Wang","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.xphs.2026.104562_bib0024","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3389\/fimmu.2020.00442","article-title":"Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools","volume":"11","author":"De Groot","year":"2020","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.xphs.2026.104562_bib0025","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.3390\/ijms26178356","article-title":"Peptides derived from \u03b1-tubulin induce functional T regulatory cells","volume":"26","author":"Fiyouzi","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.xphs.2026.104562_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011625","article-title":"Excretory\/secretory products from Schistosoma japonicum eggs alleviate ovalbumin-induced allergic airway inflammation","volume":"17","author":"Li","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.xphs.2026.104562_bib0027","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1208\/s12248-016-9948-4","article-title":"Evaluating immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics","volume":"18","author":"Jawa","year":"2016","journal-title":"AAPS J"},{"issue":"11","key":"10.1016\/j.xphs.2026.104562_bib0028","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/bit.23217","article-title":"Transforming growth factor-\u03b21 is constitutively secreted by Chinese hamster ovary cells and is functional in human cells","volume":"108","author":"Beatson","year":"2011","journal-title":"Biotechnol Bioeng"},{"issue":"6","key":"10.1016\/j.xphs.2026.104562_bib0029","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/bloodadvances.2016001842","article-title":"T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia","volume":"1","author":"Rubic-Schneider","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.xphs.2026.104562_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970499","article-title":"Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: impact of excipients","volume":"13","author":"Thacker","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2026.104562_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1730346","article-title":"Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products","volume":"16","author":"Mattei","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.xphs.2026.104562_bib0032","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/bit.27808","article-title":"High-risk\" host cell proteins (HCPs): a multi-company collaborative view","volume":"118","author":"Jones","year":"2021","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.xphs.2026.104562_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108661","article-title":"Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses","volume":"224","author":"De Groot","year":"2021","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104562_bib0034","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11095-025-03843-1","article-title":"Immunogenicity of generic peptide impurities: current orthogonal approaches","volume":"42","author":"De Groot","year":"2025","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2026.104562_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1363139","article-title":"Assessing the immunogenicity risk of salmon calcitonin peptide impurities using in silico and in vitro methods","volume":"15","author":"Roberts","year":"2024","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.xphs.2026.104562_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103714","article-title":"Immunogenicity risk assessment of synthetic peptide drugs and their impurities","volume":"28","author":"De Groot","year":"2023","journal-title":"Drug Discov Today"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926004107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926004107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:09:15Z","timestamp":1793261355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926004107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0022354926004107"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104562","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico and in vitro immunogenicity risk assessment of process- and product-related protein impurities reported in adenoviral-vectored COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}],"article-number":"104562"}}